Kimberly Rubio

Kimberly Rubio supports the National Institute of Allergy and Infectious Diseases (NIAID) in executing mission-critical procurement activities aligned with biomedical research and public health preparedness. She manages a diverse portfolio of acquisitions focused on high-containment laboratory infrastructure, diagnostic technologies, and specialized analytical instrumentation essential for infectious disease research. Her work directly enables NIAID’s strategic objectives in developing medical countermeasures and enhancing biosafety capabilities, ensuring timely access to cutting-edge scientific tools and services. Rubio typically handles complex, technical contracts requiring rigorous compliance with federal acquisition regulations and specialized scientific specifications. Her primary contractor relationships center on Quality Biological, Inc., a key provider of biological reference materials and high-containment research reagents, and GENOMIC LABS LTD, which supports advanced genomic analysis and sequencing services. These partnerships reflect a preference for specialized vendors with proven expertise in biosafety-compliant manufacturing and diagnostic development. Rubio’s procurement approach emphasizes vendor reliability, regulatory adherence, and technical scalability, fostering long-term collaborations with niche suppliers capable of meeting stringent federal biosafety and quality standards. Rubio’s contracting patterns show a strong orientation toward open competition, with 93.1% of awards issued without set-aside restrictions. The remaining 6.9% are awarded under Total Small Business Set-Asides, indicating a measured but intentional commitment to small business participation without compromising technical requirements. Her approach prioritizes capability over socioeconomic designation, aligning with NIAID’s mission-driven need for precision and performance in high-stakes research environments. Her procurement focus is concentrated in NAICS 334516 (analytical laboratory instrumentation), 325414 (biological product manufacturing), and 325413 (in-vitro diagnostic substances), reflecting deep expertise in procuring advanced diagnostic platforms, biocontainment-compatible equipment, and specialized reagents. She also supports software publishers and precision equipment maintenance vendors, underscoring her role in sustaining the technological ecosystem required for modern infectious disease research.